Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ALDX | Aldeyra Therapeutics, Inc.

IndexRUT P/E- EPS (ttm)-0.89 Insider Own2.80% Shs Outstand58.79M Perf Week-6.92%
Market Cap394.68M Forward P/E- EPS next Y-1.09 Insider Trans0.00% Shs Float46.06M Perf Month-15.17%
Income-52.10M PEG- EPS next Q-0.33 Inst Own64.90% Short Float / Ratio13.21% / 6.56 Perf Quarter-18.13%
Sales- P/S- EPS this Y0.70% Inst Trans-1.02% Short Interest6.09M Perf Half Y-14.94%
Book/sh2.21 P/B2.86 EPS next Y5.20% ROA-30.00% Target Price20.38 Perf Year3.10%
Cash/sh2.43 P/C2.60 EPS next 5Y- ROE-35.90% 52W Range4.95 - 11.97 Perf YTD-9.20%
Dividend- P/FCF- EPS past 5Y5.40% ROI- 52W High-47.20% Beta1.09
Dividend %- Quick Ratio10.00 Sales past 5Y- Gross Margin- 52W Low27.57% ATR0.29
Employees15 Current Ratio10.00 Sales Q/Q- Oper. Margin- RSI (14)26.98 Volatility4.11% 3.79%
OptionableYes Debt/Eq0.12 EPS Q/Q49.90% Profit Margin- Rel Volume0.48 Prev Close6.44
ShortableYes LT Debt/Eq0.08 EarningsAug 03 AMC Payout- Avg Volume927.25K Price6.32
Recom1.40 SMA20-12.37% SMA50-16.44% SMA200-21.02% Volume449,064 Change-1.86%
Date Action Analyst Rating Change Price Target Change
Apr-27-22Resumed H.C. Wainwright Buy $15
Feb-08-21Initiated H.C. Wainwright Buy $26
Dec-16-20Initiated Berenberg Buy $32
Oct-30-20Initiated Jefferies Buy $24
Oct-16-20Initiated BTIG Research Buy $29
Sep-22-20Initiated Alliance Global Partners Buy $32
May-12-20Initiated Oppenheimer Outperform $12
Dec-04-18Initiated Citigroup Buy $23
Sep-26-18Reiterated Cantor Fitzgerald Overweight $23 → $30
Sep-13-18Initiated Janney Buy
Jun-19-14Initiated Aegis Capital Buy $35
Aug-28-23 10:22AM
Jul-20-23 09:55AM
Jul-06-23 07:00AM
Jun-29-23 07:00AM
04:01PM Loading…
Jun-28-23 04:01PM
Jun-27-23 12:03PM
Jun-26-23 04:01PM
Jun-23-23 07:00AM
Jun-21-23 09:34AM
Jun-16-23 10:26AM
Jun-15-23 02:52PM
04:01PM Loading…
Jun-14-23 04:01PM
Jun-02-23 07:00AM
May-07-23 07:30AM
May-04-23 07:00AM
Apr-13-23 07:00AM
Apr-06-23 07:00AM
Mar-30-23 07:00AM
Mar-16-23 07:00AM
Mar-11-23 02:59AM
Mar-09-23 11:05PM
Mar-02-23 07:00AM
Mar-01-23 07:00AM
Feb-28-23 03:22PM
07:00AM Loading…
Feb-23-23 07:00AM
Feb-22-23 05:26AM
Feb-16-23 07:00AM
Feb-09-23 07:00AM
Feb-07-23 07:00AM
Jan-12-23 06:37AM
Dec-21-22 07:00AM
Dec-13-22 01:37PM
Dec-01-22 08:00AM
Nov-29-22 08:00AM
Nov-10-22 07:00AM
Nov-03-22 08:00AM
Nov-02-22 01:45PM
Oct-26-22 08:00AM
Oct-06-22 12:23PM
Oct-05-22 04:05PM
Sep-14-22 08:00AM
Sep-07-22 08:00AM
Sep-01-22 06:56AM
Aug-15-22 09:55AM
Aug-07-22 03:00AM
Aug-05-22 07:00AM
Aug-01-22 02:55PM
Jul-29-22 08:00AM
Jul-13-22 10:53AM
Jul-12-22 09:00AM
Jul-11-22 04:05PM
Jun-28-22 12:20PM
Jun-21-22 11:01AM
Jun-09-22 08:00AM
Jun-08-22 09:40AM
Jun-07-22 04:05PM
May-24-22 07:00AM
May-23-22 04:05PM
May-18-22 03:26PM
May-05-22 08:30PM
May-04-22 08:30AM
Apr-28-22 04:05PM
Apr-27-22 08:00AM
Apr-21-22 08:00AM
Apr-05-22 08:00AM
Mar-29-22 08:00AM
Mar-22-22 08:00AM
Mar-18-22 07:30AM
Mar-17-22 07:00AM
Mar-14-22 08:00AM
Mar-10-22 08:00AM
Mar-08-22 08:00AM
Mar-07-22 11:28AM
Feb-10-22 08:00AM
Feb-01-22 08:00AM
Jan-18-22 01:38PM
Jan-11-22 08:00AM
Jan-07-22 01:38PM
Jan-06-22 08:00AM
Jan-04-22 08:00AM
Dec-29-21 10:18AM
Dec-20-21 04:05PM
Dec-15-21 08:38AM
Dec-05-21 06:23AM
Nov-11-21 08:38AM
Nov-09-21 04:05PM
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment primary vitreoretinal lymphoma cancer, proliferative vitreoretinopathy, and retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Brady Todd CPresident and CEOSep 07Option Exercise0.55273,058150,7281,728,343Sep 11 05:42 PM
Phillips Gary M.DirectorSep 07Option Exercise0.555,4373,00114,812Sep 11 04:31 PM
Walker NealDirectorAug 22Option Exercise0.559,6045,30115,854Aug 24 04:13 PM
Bronstein BenDirectorJun 27Option Exercise0.559,6045,30128,248Jun 29 04:23 PM